Loading...
•
Mar 31, 2021
iTeos Therapeutics Q1 2021 Earnings Report
iTeos Therapeutics reported financial results for the first quarter ended March 31, 2021 and provided recent business highlights.
Key Takeaways
iTeos Therapeutics reported a net loss of $13.5 million for the first quarter of 2021. The company's cash and cash equivalents totaled $321.4 million, expected to provide a runway into 2023.
Presented differentiated clinical and pharmacodynamic data from Phase 1/2a trial of anti-TIGIT antibody, EOS-448, at AACR 2021.
Expansion into combination cohorts expected mid-2021
Inupadenant updated monotherapy clinical data and evidence of association of A2A receptor expression with anti-tumor activity to be presented at the ASCO 2021 Annual Meeting in June.
Strong cash balance of $321.4 million to support clinical advancements and continued investment in discovery efforts to expand pipeline.
iTeos Therapeutics
iTeos Therapeutics
Forward Guidance
iTeos expects to nominate an additional product candidate for Investigational New Drug-enabling studies before the end of 2021.